Clinical Guides
Stable Angina
A clinically focused guide to excluding acute coronary syndrome, estimating obstructive coronary disease likelihood, selecting cardiac imaging, controlling angina and preventing events in Indian practice.
MedNext Academy | 15 min read
Stable Angina
A clinically focused guide to excluding acute coronary syndrome, estimating obstructive coronary disease likelihood, selecting cardiac imaging, controlling angina and preventing events in Indian practice.
Summary
Stable angina is a reproducible symptom syndrome caused by transient myocardial ischaemia, usually during exertion or emotional stress and relieved by rest or a short-acting nitrate. The word stable describes a pattern, not a harmless disease. New pain, pain at rest, accelerating frequency, prolonged episodes, syncope, heart failure or haemodynamic instability must be assessed as possible acute coronary syndrome (ACS) rather than routed into elective testing. A normal resting electrocardiogram does not exclude coronary disease, and symptomatic improvement with glyceryl trinitrate is not a diagnostic test.
Modern chronic coronary syndrome assessment starts with a structured history, examination, resting ECG and baseline laboratory evaluation. Echocardiography identifies ventricular dysfunction or valve disease. Estimate the clinical likelihood of obstructive atherosclerotic coronary artery disease using age, sex, symptoms and risk factors, then select anatomical or functional imaging according to likelihood, patient characteristics, the clinical question, local expertise and availability. Coronary CT angiography is especially useful at low-to-moderate likelihood; stress imaging adds evidence of ischaemia and risk. Invasive angiography is reserved for high likelihood, high-risk findings, severe low-threshold symptoms, refractory angina or a likely need for revascularisation.
Treatment has separate goals. Short-acting nitrate and one or two appropriate antianginal agents improve symptoms. Smoking cessation, physical activity, lipid lowering, blood-pressure and diabetes care, antithrombotic treatment when indicated, cardiac rehabilitation and adherence reduce future events. Revascularisation can provide greater symptom relief and is prognostically important for selected high-risk anatomy or ventricular dysfunction, but routine invasive treatment does not improve survival for every stable patient. Women, people with diabetes and those with angina despite non-obstructive arteries require the same diagnostic seriousness without assuming the same mechanism or procedural benefit.
How Common Is It?
Stable angina is one presentation within the broader burden of ischaemic heart disease, and prevalence estimates depend on whether surveys count symptoms, physician diagnosis, positive testing, prior infarction or established obstructive disease. Symptom questionnaires can overcount reflux or musculoskeletal pain, while registries miss undiagnosed disease and people with limited access. The India State-Level Disease Burden Initiative estimated 23.8 million prevalent ischaemic heart disease cases in India in 2016, but that figure includes more than stable angina and should not be relabelled as an angina prevalence. It also showed major differences between states, warning against treating one national average as local reality.
The probability of obstructive coronary disease rises with age and risk-factor burden, but symptoms and mechanisms differ. Women with chronic coronary syndromes often report dyspnoea, fatigue or variable discomfort and have a higher frequency of coronary microvascular dysfunction than men. Calling these symptoms atypical can create under-investigation. Conversely, screening asymptomatic people with advanced imaging has not been proved beneficial simply because diabetes or another risk factor is present. Clinical testing should answer a defined question rather than respond to population anxiety.
Indian service data are shaped by urban-rural access, out-of-pocket cost, availability of CT, stress imaging and invasive laboratories, and referral selection. Hospital angiography cohorts cannot estimate community prevalence. A high proportion of diabetes, hypertension, tobacco exposure and dyslipidaemia makes prevention urgent, but it does not mean every chest symptom is atherosclerotic angina. Good local measurement separates suspected symptoms, confirmed obstructive disease, inducible ischaemia, previous infarction and angina with non-obstructive coronary arteries, and reports sex, age, state and care setting.
Risk Factors
Atherosclerotic obstructive coronary disease is more likely with increasing age, diabetes, hypertension, dyslipidaemia, smoking or smokeless tobacco, chronic kidney disease, central adiposity, family history of premature cardiovascular disease and established vascular disease in another territory. Risk factors influence clinical likelihood and long-term events but do not confirm that today's pain is ischaemic. Severe anaemia, thyrotoxicosis, tachyarrhythmia, uncontrolled blood pressure and aortic stenosis can increase myocardial demand or reduce oxygen delivery, producing or worsening angina even when epicardial stenosis is modest.
Once chronic coronary disease is established, adverse prognosis is associated with left-ventricular systolic dysfunction, heart failure, chronic kidney disease, diabetes, extensive ischaemia, left-main or multivessel disease, previous myocardial infarction, persistent smoking and poor control of lipids or blood pressure. Frailty, depression, low health literacy, medicine cost and fragmented follow-up can undermine prevention. The risk of bleeding must be considered separately when prescribing antithrombotic therapy. An intervention that lowers thrombotic risk may cause net harm when bleeding risk, interactions or adherence are ignored.
Women are often evaluated later and may have less obstructive epicardial disease despite genuine ischaemia. The same preventive therapy should be offered when indicated, while pregnancy potential, menopause, autoimmune disease and bleeding history inform individual decisions. Diabetes increases diffuse and multivessel disease, can blunt classic pain, and affects the balance between PCI and CABG when revascularisation is necessary. Yet neither sex nor diabetes should be used as a shortcut to catheterisation. Risk assessment should distinguish: probability of obstructive disease, immediate probability of ACS, future cardiovascular-event risk, treatment toxicity and likelihood that a particular symptom will improve with revascularisation.
Diagnosis
History
First decide whether the presentation is stable enough for elective assessment. Ask about onset, site, character, radiation, duration, exertional threshold, emotional or cold trigger, relief with rest, trajectory and associated dyspnoea, sweating, nausea, palpitation or syncope. Typical angina has constricting chest or arm discomfort, is provoked by exertion and improves with rest or nitrate, but descriptors vary. Identify rest pain, prolonged or accelerating episodes, a recent major change and low-threshold symptoms. Record prior infarction or revascularisation, vascular risk, kidney disease, bleeding, erectile-dysfunction treatment, pregnancy possibility, functional limitation, medicines and adherence.
Examination
Measure pulse, blood pressure in both arms when relevant, oxygen saturation and body mass index. Look for heart failure, anaemia, thyroid disease, peripheral vascular disease, xanthomata and tobacco-related disease. Auscultate for aortic stenosis, hypertrophic cardiomyopathy and other valve lesions. Chest-wall tenderness supports a musculoskeletal contributor but does not exclude coexisting coronary disease. During pain, hypotension, pulmonary oedema, a new murmur or arrhythmia requires urgent escalation.
Investigations
Obtain a 12-lead ECG; acute changes or ongoing pain trigger an ACS pathway with serial ECG and high-sensitivity troponin, not outpatient stress testing. Baseline tests commonly include full blood count, renal function, glucose or HbA1c and lipids. Resting echocardiography assesses ventricular function and valve disease. Estimate risk-factor-weighted clinical likelihood. At very low likelihood, consider alternative diagnoses and deferring cardiac testing. At low-to-moderate likelihood, coronary CT angiography can exclude or define obstructive plaque. At moderate-to-high likelihood, stress echocardiography, perfusion CMR, PET or SPECT may define inducible ischaemia, chosen by availability and patient factors. Exercise ECG alone is less accurate for diagnosis but can assess exercise tolerance where appropriate. Use invasive angiography for high-risk or refractory cases and apply physiological lesion assessment when anatomy alone does not establish significance.
Differential Diagnosis
Acute coronary syndrome is the first exclusion, not simply another line in a list. Unstable angina or infarction may present with new or worsening exertional pain, rest pain, prolonged discomfort, autonomic symptoms or breathlessness. Aortic dissection, pulmonary embolism, pneumothorax, myocarditis and pericarditis are other time-critical alternatives. Severe aortic stenosis, hypertrophic cardiomyopathy, tachyarrhythmia, hypertensive crisis, profound anaemia or hypoxaemia can produce myocardial supply-demand mismatch and need their own urgent pathway.
Common non-cardiac causes include gastro-oesophageal reflux, oesophageal spasm, peptic disease, costochondritis, cervical radiculopathy, shoulder pathology, anxiety and panic. Reproducibility with palpation or relation to meals can shift probability, but no isolated feature safely excludes coronary disease in a high-risk patient. Shortness of breath may reflect heart failure, lung disease, obesity, deconditioning or anaemia. A response to nitrate is nonspecific because oesophageal spasm can also improve, while true angina may persist despite nitrate.
Not all cardiac ischaemia is caused by a fixed obstructive plaque. Coronary vasospasm often occurs at rest, sometimes with transient ST change. Microvascular angina and other ANOCA/INOCA endotypes can produce exertional or rest symptoms with non-obstructive CT or angiography; they are more frequently recognized in women but occur in all sexes. A negative anatomical test should prompt reconsideration of mechanism rather than dismissal when symptoms are convincing. Prior stenting introduces restenosis and disease progression, while post-CABG symptoms may arise from graft or native-vessel disease. The final working diagnosis should state whether coronary disease is suspected or confirmed, whether ACS was excluded, the proposed ischaemic mechanism and which important alternatives remain unresolved.
Management
Give every patient a plan for an acute episode. Stop exertion, sit or rest safely and use prescribed short-acting glyceryl trinitrate. If pain persists, follow the emergency sequence rather than repeatedly self-treating an evolving infarction: Current guidelines advises a second dose after five minutes and ambulance activation if pain remains five minutes later. Any episode that is more intense, prolonged, occurs at rest or accompanies breathlessness, sweating, syncope or weakness deserves urgent assessment sooner. Explain that symptom medicines do not remove plaque or replace prevention.
For chronic control, select a beta-blocker or calcium-channel blocker first, guided by heart rate, blood pressure, ventricular function, conduction, bronchospasm, comorbidity and patient preference. Review within weeks, titrate to benefit and tolerance, switch or combine rationally, and use a dihydropyridine calcium-channel blocker when adding one to a beta-blocker. Long-acting nitrate, ranolazine, ivabradine or nicorandil may suit selected patients when first-line options fail or are contraindicated. Reassess diagnosis and adherence before accumulating drugs. Cardiac rehabilitation, progressive physical activity, tobacco cessation, diet, weight, sleep and psychological support are active treatment.
Secondary prevention includes potent lipid lowering, blood-pressure and diabetes management, and antiplatelet treatment according to established disease, bleeding risk and any prior PCI or ACS. ACE inhibition or renin-angiotensin-system therapy is particularly relevant with diabetes, hypertension, kidney disease or ventricular dysfunction. Revascularisation is considered for unacceptable symptoms despite guideline-directed therapy, high-risk anatomy, significant left-main disease or selected ventricular dysfunction. PCI and CABG choice depends on anatomy, diabetes, surgical risk, ventricular function, expected completeness, repeat-procedure risk and preference, ideally through a heart team. Continue preventive therapy after a procedure; a stent does not cure systemic atherosclerosis.
Prescribing Information
Short-acting glyceryl trinitrate is used under the tongue for an episode or immediately before predictable exertion. Teach storage, priming where relevant, sitting before use and the emergency time rule. Headache, flushing and light-headedness are common. Nitrates can cause profound hypotension with phosphodiesterase-5 inhibitors used for erectile dysfunction or pulmonary hypertension; ask directly and give explicit separation advice based on the specific drug and current formulary guidance. Avoid routine nitrate use in marked hypotension, critical aortic stenosis or suspected right-ventricular infarction until expert assessment. Long-acting preparations need a nitrate-free interval to limit tolerance.
Beta-blockers reduce heart rate and demand but can cause bradycardia, hypotension, fatigue, sexual dysfunction and bronchospasm; do not stop abruptly. Non-dihydropyridine calcium-channel blockers can worsen bradycardia, conduction block or reduced-ejection-fraction heart failure and should not be casually combined with a beta-blocker. Dihydropyridines may cause ankle oedema and headache. Ivabradine is used only in sinus rhythm with an appropriate resting heart rate and has bradycardia and atrial-fibrillation concerns. Ranolazine can prolong QT and interacts through CYP pathways. Nicorandil can cause serious ulceration. Individual product licensing and availability must be checked in India.
Aspirin is commonly used in established atherosclerotic coronary disease after assessing gastrointestinal, intracranial and other bleeding risks. Antiplatelet duration after PCI or ACS is not determined by the label stable angina alone; it depends on procedure, stent, presentation, ischaemic and bleeding risks, and concomitant anticoagulation. Statins require adherence support and evaluation of adverse symptoms without abandoning prevention after one intolerance. Diabetes therapies with cardiovascular benefit may be indicated according to diabetes, kidney and heart-failure status. Monitor renal function, potassium, blood pressure, lipids, glucose and interactions according to the chosen regimen.
When to Refer
Use emergency referral for ongoing or rest pain, a sudden change from the established pattern, haemodynamic instability, acute heart failure, syncope, malignant arrhythmia, dynamic ECG change or suspected ACS. Do not send such a patient for a routine clinic appointment or elective treadmill test. Severe anaemia, critical valve disease, pulmonary embolism or aortic syndrome requires an equally urgent alternative pathway. A patient with persistent pain should not drive. Share the ECG, symptom onset, serial observations, medicines already taken, allergies, renal function and relevant prior coronary records.
Refer to cardiology for diagnostic uncertainty with meaningful clinical likelihood, abnormal CT or stress imaging, left-ventricular dysfunction, exertional syncope, unacceptable symptoms, low-threshold angina, suspected vasospasm or microvascular disease, or difficulty selecting treatment because of comorbidity. Invasive angiography is appropriate when test findings predict high event risk, symptoms remain severe despite medical therapy, or revascularisation is being considered. A heart-team discussion is important for left-main disease, complex multivessel disease, diabetes with multivessel involvement, reduced ventricular function or uncertainty between PCI and CABG.
Referral should state the question. Include symptom pattern and functional class, why ACS is not suspected now, risk factors, sex-specific or atypical features, ECG, echocardiogram, laboratory results, prior imaging, current doses, adherence, adverse effects, bleeding risk and patient goals. Refractory symptoms after apparently successful revascularisation deserve comprehensive reassessment rather than serial procedures: consider restenosis, incomplete revascularisation, vasospasm, microvascular dysfunction and non-cardiac pain. Cardiac rehabilitation and prevention follow-up should continue locally while specialist evaluation proceeds. Lack of access to one ideal test should prompt a documented alternative strategy, not indefinite symptomatic prescribing without diagnostic review.
Red Flags
Assume possible ACS when chest discomfort is new, occurs at rest, lasts longer than the patient's usual episodes, increases in frequency or severity, appears at a much lower workload, or no longer responds normally to rest or nitrate. Associated sweating, nausea, dyspnoea, profound weakness, syncope or a sense of impending collapse increases concern. Women, older adults and people with diabetes may present with breathlessness, fatigue, epigastric discomfort or altered function rather than a textbook central pain description. Obtain an immediate ECG and follow the current ACS troponin pathway; an initially normal ECG cannot close the diagnosis.
Haemodynamic instability, pulmonary oedema, oxygen desaturation, sustained ventricular arrhythmia, new conduction abnormality or a new murmur requires resuscitation and urgent cardiology assessment. Tearing pain with pulse or neurological asymmetry suggests aortic dissection; pleuritic pain with hypoxaemia or risk factors suggests pulmonary embolism; sudden unilateral absent breath sounds suggests pneumothorax. These diagnoses can coexist with coronary risk and should not be forced into a stable-angina label. Exercise testing is contraindicated during an unstable presentation.
High-risk chronic findings also need accelerated specialist review: left-main or extensive proximal disease, large ischaemic burden, ejection-fraction reduction, angina at minimal activity, progressive heart failure, or symptoms despite tolerated multidrug therapy. Prescribing red flags include nitrate use with a recent phosphodiesterase-5 inhibitor, symptomatic bradycardia from rate-limiting drugs, hypotension, QT prolongation with interacting medicines, serious nicorandil ulceration, antithrombotic bleeding and abrupt beta-blocker withdrawal. After PCI, recurrent pain plus ECG change or instability is an emergency; early reassurance based on the existence of a stent is unsafe.
Indian Clinical Context
India carries a large and uneven ischaemic-heart-disease burden, while CT angiography, high-quality stress imaging, cardiac rehabilitation and interventional services are concentrated in some cities and private systems. The diagnostic plan should be both evidence-based and executable. Before ordering an expensive test, define whether the question is exclusion of obstructive plaque, demonstration of inducible ischaemia, assessment of ventricular or valve disease, or planning revascularisation. A high-quality CT may be more informative than an indiscriminate treadmill test, but heavy calcification, arrhythmia, renal impairment, contrast allergy and local image expertise change that choice. Document why an alternative is used.
Cost discussions must include downstream consequences: repeat visits after an equivocal test, travel, time away from work, long-term medicines, dual antiplatelet therapy, rehabilitation and possible repeat revascularisation. Check eligibility for PM-JAY or a state scheme without promising coverage. Generic medicines can improve access, but brand substitution, fixed-dose combinations and fragmented prescriptions increase duplication or interaction risk. Record generic names and doses, reconcile therapy at every transition, and make nitrate–erectile-dysfunction interactions discussable without stigma. Tobacco counselling must include bidis, smokeless products and second-hand exposure.
Women and people with diabetes are vulnerable to diagnostic shortcuts. Do not downgrade exertional dyspnoea or fatigue because pain is absent, and do not assume a normal angiogram proves symptoms are psychological. Conversely, diabetes alone is not an indication for routine invasive angiography in an asymptomatic person. Where ANOCA/INOCA testing is unavailable, acknowledge uncertainty, treat vascular risk, trial mechanism-informed symptom therapy under cardiology care and safety-net carefully. Explain that PCI commonly improves angina when symptoms arise from a treatable stenosis but does not provide universal survival benefit in stable normal-ventricular-function disease. Shared decisions should compare medical therapy, PCI and CABG using the actual anatomy, diabetes status, ventricular function, local outcomes, affordability and the person's priorities.
NMC Competency Mapping
Stable angina integrates internal medicine, physiology, pharmacology, pathology, radiology and community medicine. Knowledge outcomes include coronary atherosclerosis, determinants of myocardial oxygen supply and demand, plaque stability, collateral circulation and differences among stable angina, unstable angina and infarction. Learners should recognize vascular risk factors without equating them with a diagnosis, explain the three-feature symptom pattern, and understand why women and people with diabetes may not present with classic pain. They should connect ECG physiology to ischaemic change while knowing that a resting trace may be normal.
Clinical skills include taking a timed chest-pain history, identifying ACS red flags, examining for heart failure and valve disease, recording a 12-lead ECG promptly, and selecting baseline tests. At an applied level, the learner should estimate clinical likelihood, explain when CT angiography or stress imaging is informative, and avoid using exercise ECG during instability. Prescribing competence includes safe short-acting nitrate instructions, recognition of phosphodiesterase-5 inhibitor interaction, rational selection of beta-blocker or calcium-channel blocker, lipid lowering, antiplatelet risk assessment and monitoring.
Decision competence is demonstrated by separating symptom relief from event prevention and prognostic revascularisation. Students should explain why a stent can improve angina without curing systemic disease, and why anatomy, functional significance, ventricular function, diabetes and patient preference guide PCI versus CABG. They should refer unstable symptoms immediately and hand over structured data. Advanced coronary physiology, invasive ANOCA testing and procedural selection remain specialist tasks. Exact codes should be checked against the NMC curriculum and local logbook currently implemented; the educational plan should not fabricate a narrow code when the topic spans multiple competencies.
Key Exam Pearls for NEET PG
Typical stable angina is constricting discomfort in the chest, neck, jaw, shoulder or arm, precipitated by exertion and relieved by rest or nitrate. Three features make typical angina, two atypical angina and one or none non-anginal pain in classic symptom classification, but no label overrides ACS red flags. Rest pain, crescendo symptoms, prolonged discomfort or a fall in exertional threshold requires acute assessment. Nitrate response is not diagnostic. A normal resting ECG does not exclude disease. Baseline echocardiography evaluates ventricular function and valve disease.
Current chronic-coronary-syndrome assessment uses risk-factor-weighted clinical likelihood. At very low likelihood, testing can often be deferred. Coronary CT angiography is strong for low-to-moderate likelihood and anatomical exclusion; functional imaging demonstrates inducible ischaemia and helps risk assessment at moderate-to-high likelihood. Invasive angiography is used for high likelihood, high-risk findings, severe refractory symptoms or revascularisation planning, with physiological assessment of intermediate lesions. Non-obstructive arteries do not exclude vasospastic or microvascular angina.
Give short-acting nitrate for attacks and usually a beta-blocker or calcium-channel blocker for prevention. Combine a beta-blocker with a dihydropyridine, not casually with verapamil or diltiazem. Secondary prevention addresses tobacco, exercise, lipids, blood pressure, diabetes and antithrombotic therapy. Revascularisation primarily improves symptoms in many stable patients; it is prognostically important in selected high-risk anatomy or dysfunction. ISCHEMIA did not show that an initial invasive strategy reduced overall death or ischaemic events in its studied stable population, and excluded important groups, so its result is neither a ban on revascularisation nor proof that every patient benefits.
Frequently Asked Questions
How can a clinician distinguish stable angina from an acute coronary syndrome?
A long-standing reproducible exertional pattern that resolves with rest supports stable angina, but a new episode, rest pain, longer duration, increasing frequency or severity, a lower trigger threshold, autonomic symptoms, syncope or instability requires an ACS pathway. Obtain an immediate ECG and serial high-sensitivity troponin according to protocol. Neither nitrate response nor one normal ECG safely excludes ACS.
Which test is preferred when obstructive coronary disease is suspected?
There is no single test for everyone. First estimate risk-factor-weighted clinical likelihood and assess renal function, rhythm, calcification, exercise ability and local expertise. Coronary CT angiography is useful at low-to-moderate likelihood; stress echocardiography, perfusion CMR, PET or SPECT can demonstrate ischaemia at moderate-to-high likelihood. High-risk or refractory cases may need invasive angiography and lesion physiology.
Does coronary stenting prevent death in every person with stable angina?
No. PCI often improves symptoms when a flow-limiting stenosis causes angina, but an initial invasive strategy did not reduce death or overall ischaemic events in the main ISCHEMIA population over its reported follow-up. That trial had eligibility limits. Prognostic benefit depends on anatomy, ventricular function and clinical setting; left-main disease and selected complex or dysfunctional-heart cases require separate heart-team assessment.
Should women or people with diabetes be investigated differently for stable angina?
They deserve the same diagnostic seriousness and indicated prevention, but mechanism and presentation may differ. Women more often have dyspnoea, fatigue or microvascular dysfunction; diabetes may blunt pain and increases diffuse multivessel disease. Neither characteristic alone mandates angiography. Use symptoms, risk factors, likelihood, imaging, ventricular function and goals. Diabetes meaningfully influences CABG-versus-PCI decisions when complex multivessel revascularisation is needed.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic